Blake Scholl joins the Loyal Board of Directors
Loyal Founder and CEO, Celine Halioua, introduces the newest addition to our Board of Directors
March 10, 2023
Loyal’s latest milestone: the first longevity clinical study design supported by the FDA
At Loyal we’re developing the first FDA-approved drugs explicitly intended to extend lifespan and healthspan, and being first means charting new waters.
On the path to FDA approval, we must run a clinical trial that objectively and robustly demonstrates that our drug extends dogs’ healthy lifespan, and does so safely. Because no one has developed a dog — or human — longevity drug before, we are building the path to FDA approval largely from scratch.
Last week we learned from the FDA that Loyal received protocol concurrence for our companion dog longevity study — likely the first time the FDA has given their blessing to a longevity clinical trial. Our regulatory expert Karen Greenwood weighs in on what this means for Loyal, for the field of aging, and for dogs everywhere.
→
At Loyal we’re developing the first FDA-approved drugs explicitly intended to extend lifespan and healthspan, and being first means charting new waters.
On the path to FDA approval, we must run a clinical trial that objectively and robustly demonstrates that our drug extends dogs’ healthy lifespan, and does so safely. Because no one has developed a dog — or human — longevity drug before, we are building the path to FDA approval largely from scratch.
Last week we learned from the FDA that Loyal received protocol concurrence for our companion dog longevity study — likely the first time the FDA has given their blessing to a longevity clinical trial. Our regulatory expert Karen Greenwood weighs in on what this means for Loyal, for the field of aging, and for dogs everywhere.